REDWOOD CITY, Calif.
July 1, 2013
/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that on
July 9, 2013
the Company will participate in the Piper Jaffray Catalyst Symposium in
July 10, 2013
, President and CEO, will present a corporate overview at the JMP Securities Healthcare Conference 2013 at the St. Regis New York in
New York, NY
. Details of these two events are as follows:
Piper Jaffray Catalyst Symposium: Emerging Talent in BioPharma
Tuesday, July 9, 2013
Ritz-Carlton Boston Common, Boston, MA
JMP Securities Healthcare Conference 2013
Wednesday, July 10, 2013
The St. Regis New York in NY, NY
12:30 pm ET, 9:30 am PT
The JMP presentation will be webcast live and can be accessed through the Investors page at
. For those not available to listen to the live broadcast, a replay of the presentations will be archived for 90 days and available through the Investors page on
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. Zalviso™, AcelRx's lead product candidate, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. Zalviso has successfully completed all three of its planned Phase 3 clinical trials and a New Drug Application submission is planned for the third quarter of 2013. AcelRx has announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from U.S. Army Medical Research and Materiel Command. The Company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development. For additional information about AcelRx's clinical programs please visit
Forward Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to Zalviso, and the therapeutic potential of AcelRx Pharmaceuticals' product candidates, the Company's planned New Drug Application submission, planned or anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, and the therapeutic potential of AcelRx Pharmaceuticals' product candidates. These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx Pharmaceuticals' product development activities and clinical trials; the market potential for its product candidates; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission filings, including its Quarterly Report on Form 10-Q filed with the SEC on
May 8, 2013
. AcelRx Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.
SOURCE AcelRx Pharmaceuticals, Inc.